|
2023-08-22 |
2023-08-21 |
B
Purchase
|
Kandera Reinhard
Chief Financial Officer
Executive Director
|
7,000
+19.4%
0.73
USD 5,075
|
7,000
+19.4%
|
0.73
|
USD 5,075
|
|
|
2023-08-17 |
2023-08-16 |
B
Purchase
|
Kandera Reinhard
Chief Financial Officer
Executive Director
|
8,000
+28.5%
0.71
USD 5,712
|
8,000
+28.5%
|
0.71
|
USD 5,712
|
|
|
2023-07-11 |
2023-07-11 |
B
Purchase
|
Aldag Jorn
Chief Executive Officer
Executive Director
|
5,000
+7.5%
0.83
USD 4,142
|
5,000
+7.5%
|
0.83
|
USD 4,142
|
|
|
2023-07-11 |
2023-07-07 |
B
Purchase
|
Aldag Jorn
Chief Executive Officer
Executive Director
|
5,000
+8.1%
0.81
USD 4,050
|
5,000
+8.1%
|
0.81
|
USD 4,050
|
|
|
2023-07-07 |
2023-07-05 |
B
Purchase
|
Aldag Jorn
Chief Executive Officer
Executive Director
|
5,000
+8.8%
0.89
USD 4,450
|
5,000
+8.8%
|
0.89
|
USD 4,450
|
|
|
2023-07-05 |
2023-07-03 |
B
Purchase
|
Aldag Jorn
Chief Executive Officer
Executive Director
|
5,000
+9.6%
0.89
USD 4,456
|
5,000
+9.6%
|
0.89
|
USD 4,456
|
|
|
2023-07-03 |
2023-06-30 |
B
Purchase
|
Kandera Reinhard
Chief Financial Officer
Executive Director
|
12,000
+74.6%
0.88
USD 10,560
|
12,000
+74.6%
|
0.88
|
USD 10,560
|
|
|
2022-01-12 |
2021-12-21 |
S
Sale
|
Matushansky Igor
Chief Medical Officer
Officer
|
2,205
-2.5%
2.49
USD
|
2,205
-2.5%
|
2.49
|
USD 5,490
|
|
|
2022-01-12 |
2021-12-21 |
S
Sale
|
Matushansky Igor
Chief Medical Officer
Officer
|
7,440
-8.1%
2.49
USD
|
7,440
-8.1%
|
2.49
|
USD 18,526
|
|
|
2022-01-12 |
2021-12-21 |
S
Sale
|
Matushansky Igor
Chief Medical Officer
Officer
|
5,304
-6.2%
2.49
USD
|
5,304
-6.2%
|
2.49
|
USD 13,207
|
|
|
2021-04-23 |
2021-04-21 |
S
Sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
328,620
-9.4%
11.60
USD
|
328,620
-9.4%
|
11.60
|
USD 3,812,386
|
|
|
2021-03-29 |
2021-03-25 |
PS
Planned sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
28,546
-0.8%
13.12
USD
|
28,546
-0.8%
|
13.12
|
USD 374,569
|
|
|
2021-03-26 |
2021-03-24 |
PS
Planned sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
52,690
-1.4%
13.70
USD
|
52,690
-1.4%
|
13.70
|
USD 721,616
|
|
|
2021-03-25 |
2021-03-23 |
PS
Planned sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
40,000
-1.1%
13.91
USD
|
40,000
-1.1%
|
13.91
|
USD 556,476
|
|
|
2021-03-24 |
2021-03-22 |
PS
Planned sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
40,534
-1.1%
14.54
USD
|
40,534
-1.1%
|
14.54
|
USD 589,263
|
|
|
2021-03-23 |
2021-03-19 |
PS
Planned sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
166,230
-4.3%
14.60
USD
|
166,230
-4.3%
|
14.60
|
USD 2,427,739
|
|
|
2020-12-18 |
2020-12-17 |
S
Sale
|
Matushansky Igor
Chief Medical Officer
Officer
|
16,478
-17.6%
11.76
USD
|
16,478
-17.6%
|
11.76
|
USD 193,781
|
|
|
2020-12-18 |
2020-12-17 |
S
Sale
|
Matushansky Igor
Chief Medical Officer
Officer
|
11,501
-15.2%
11.70
USD
|
11,501
-15.2%
|
11.70
|
USD 134,562
|
|
|
2020-12-18 |
2020-12-16 |
S
Sale
|
Matushansky Igor
Chief Medical Officer
Officer
|
380
-0.7%
11.70
USD
|
380
-0.7%
|
11.70
|
USD 4,446
|
|
|
2020-10-06 |
2020-10-02 |
PS
Planned sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
300
-0.0%
10.00
USD
|
300
-0.0%
|
10.00
|
USD 3,000
|
|
|
2020-09-17 |
2020-09-15 |
PS
Planned sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
9,261
-0.2%
13.16
USD
|
9,261
-0.2%
|
13.16
|
USD 121,913
|
|
|
2020-09-17 |
2020-09-15 |
PS
Planned sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
32,336
-0.8%
12.45
USD
|
32,336
-0.8%
|
12.45
|
USD 402,564
|
|
|
2020-07-22 |
2020-07-20 |
PS
Planned sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
12,483
-0.3%
11.94
USD
|
12,483
-0.3%
|
11.94
|
USD 149,102
|
|
|
2020-07-22 |
2020-06-29 |
PS
Planned sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
3,280
-0.1%
11.78
USD
|
3,280
-0.1%
|
11.78
|
USD 38,628
|
|
|
2020-07-01 |
2020-06-29 |
PS
Planned sale
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
3,280
-0.1%
11.78
USD
|
3,280
-0.1%
|
11.78
|
USD 38,628
|
|
|
2020-01-31 |
2020-01-29 |
S
Sale
|
Matushansky Igor
Chief Medical Officer
|
5,500
-9.3%
12.73
USD
|
5,500
-9.3%
|
12.73
|
USD 69,992
|
|
|
2020-01-27 |
2020-01-23 |
S
Sale
|
Lilja Anders
Sr. VP, Technical Development
|
7,568
-100.0%
12.81
USD
|
7,568
-100.0%
|
12.81
|
USD 96,932
|
|
|
2020-01-27 |
2020-01-23 |
S
Sale
|
Lilja Anders
Sr. VP, Technical Development
|
4,075
-100.0%
12.17
USD
|
4,075
-100.0%
|
12.17
|
USD 49,601
|
|
|
2020-01-21 |
2020-01-21 |
S
Sale
|
Orlinger Klaus
Sr. VP, Research
|
6,789
-100.0%
12.02
USD
|
6,789
-100.0%
|
12.02
|
USD 81,592
|
|
|
2020-01-21 |
2020-01-16 |
S
Sale
|
Orlinger Klaus
Sr. VP, Research
|
1,711
-100.0%
11.56
USD
|
1,711
-100.0%
|
11.56
|
USD 19,781
|
|
|
2020-01-16 |
2020-01-14 |
S
Sale
|
Orlinger Klaus
Sr. VP, Research
|
8,500
-100.0%
11.30
USD
|
8,500
-100.0%
|
11.30
|
USD 96,053
|
|
|
2019-12-23 |
2019-12-19 |
S
Sale
|
Matushansky Igor
Chief Medical Officer
Officer
|
10,404
-15.0%
9.93
USD
|
10,404
-15.0%
|
9.93
|
USD 103,312
|
|
|
2019-12-19 |
2019-12-17 |
S
Sale
|
Matushansky Igor
Chief Medical Officer
Officer
|
11,484
-20.9%
7.87
USD
|
11,484
-20.9%
|
7.87
|
USD 90,379
|
|
|
2019-04-25 |
2019-04-23 |
B
Purchase
|
Forbion Capital Fund II Cooperatief U.A.
Large shareholder
|
53,571
+2.2%
14.00
USD
|
53,571
+2.2%
|
14.00
|
USD 749,994
|
|
|
2019-04-25 |
2019-04-23 |
B
Purchase
|
SOFINNOVA CAPITAL VI FCPR
Large shareholder
|
357,142
+9.9%
14.00
USD
|
357,142
+9.9%
|
14.00
|
USD 4,999,988
|
|
|
2019-04-23 |
2019-04-23 |
B
Purchase
|
BAKER BROS. ADVISORS LP
Former 10% owner
|
820,729
+inf%
14.00
USD
|
820,729
+inf%
|
14.00
|
USD 11,490,206
|
|
|
2019-04-23 |
2019-04-23 |
B
Purchase
|
BAKER BROS. ADVISORS LP
Former 10% owner
|
72,128
+inf%
14.00
USD
|
72,128
+inf%
|
14.00
|
USD 1,009,792
|
|
